2008, Volume 15, Issue 01, pages 1-56

There is a need  to meet the demand, led by primary care, for the appropriate assessment and management of patients with heart failure. Standard 11...

As part of a larger focus on prevention of disease in the NHS, Prime Minister Gordon Brown has announced that new screening programmes for early...

The first clinical trials with the new cholesteryl ester transfer protein (CETP) inhibitor, anacetrapib, have raised hopes that this agent may not be affected by...

As well as causing musculoskeletal problems, vitamin D deficiency may also increase the risk of heart disease, a new study...

Anatomy software developer, Primal Pictures, has been awarded government grants to develop two new computer simulations which should improve training procedures for cardiologists and keyhole...

Another study has suggested increased risk of cardiovascular (CV) events with the diabetes drug, rosiglitazone. In the retrospective case-control study (JAMA 2007;298:2634–43), rosiglitazone was associated...

The UK Human Fertilisation and Embryology Authority (HFEA) has granted permission for pre-implantation genetic diagnosis of familial hypercholesterolaemia (FH) to be performed for the first...

Being unfit is an independent predictor of all-cause mortality, even after adjustment for body fat, according to a new study (JAMA 2007;...

Genzyme has launched its new non-absorbed cholesterol-lowering agent, colesevelam hydrochloride (CholestagelTM) in Europe for the treatment of adult patients with primary hypercholesterolaemia who cannot meet...

A study, published in the European Heart Journal (7th January issue), has shown that people who drink moderate amounts of alcohol and are physically active...

Cardiologists from St Mary’s Hospital, London, have become the first in the world to implant a new generation of pacemaker that could help more people...

A new stent which may promote healing of the artery better than currently available drug-eluting stents has shown promising results in initial clinical trials. The...

The first study to investigate the efficacy of the cholesterol absorption inhibitor, ezetimibe, has shown no benefit of the drug in an imaging study in...

State-of-the-art virtual simulators (see right) and a virtual in-house catheterisation laboratory to help physicians learn about the latest cardiac and vascular treatment techniques are just...

Does the transradial route for percutaneous coronary intervention preclude the use of the radial artery as a conduit for...

The Second Scientific Meeting of the Cardiorenal Forum (CRF) was held recently at the Royal Pharmaceutical Society in London. This well-attended meeting highlighted the growing...

The dramatic improvement in the management of cardiovascular disease over the past decade and the challenges that lie ahead were key elements of ‘Looking to...

We continue our series in which Consultant Interventionist Dr Michael Norell takes a sideways look at life in the cath lab…and beyond. In this column,...

This book is aimed at cardiologists as well as more general medical practitioners wanting to improve their knowledge of this area....

A 60-year-old male was admitted acutely unwell with prolonged ischaemic chest pain. Seven weeks earlier he had undergone percutaneous coronary intervention (PCI) following admission with...